Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatment of serious diseases with significant unmet medical needs in the orphan drug segment.

Emcitate® (tiratricol)

Our lead product candidate

Pipeline

Corporate presentation

Press Releases

March 9, 2026

Egetis Receives Notice of Allowance for MCT8 Deficiency Composition Patent in the U.S.

Read more

March 2, 2026

Egetis Therapeutics Launches Educational Websites on MCT8 Deficiency for Physicians and Caregivers

Read more

Regulatory

February 26, 2026

Year-End Report January-December 2025

Read more

Upcoming event

March 11, 2026

Leerink Global Healthcare Conference (fireside chat with Nicklas Westerholm)

Latest presentation

February 26, 2026

Q4 2025 report webcast (replay)

Latest Report

February 26, 2026

Full year report 2025

Calendar and upcoming reports

March 11, 2026

Leerink Global Healthcare Conference (Miami, FL)

March 12, 2026

DNB Carnegie Healthcare Conference (Stockholm)

April 14, 2026

Annual General Meeting

April 16, 2026

van Lanschot Kempen Life Sciences Conference (Amsterdam)

April 29, 2026 (7:00am CEST)

Interim Report Q1 2026

Joshua’s Story

Share

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]